Physician profile
Ruby Marisela Barquist
NPI 1932877446
$549.42
in general payments reported to CMS, 2019-2025
11 companies · $146 in 2025
The $146 reported for 2025 was more than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5.27 · 2022: $129 · 2023: $106 · 2024: $163 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $258.75 | 2023-2025 | Azstarys, Azstarys |
| Merck Sharp & Dohme LLC | $59.63 | 2024-2025 | Gardasil 9, Vaxelis, Gardasil |
| Depuy Synthes Sales INC. | $50.28 | 2022 | |
| Neurelis, INC. | $44.67 | 2022 | |
| Glaxosmithkline, LLC. | $33.82 | 2022 | |
| Biomarin Pharmaceutical INC. | $24.88 | 2024 | Voxzogo 1.2mg |
| Sanofi Pasteur INC. | $22.07 | 2023 | |
| Abbvie INC. | $21.36 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $14.67 | 2024 | Flumist Quadrivalent |
| Lundbeck LLC | $14.02 | 2023 | Vyepti |
| Genentech USA, INC. | $5.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Barquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.